Part ‘B’: Associates and joint venture companies Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to joint arrangements (` cr) No. Name of the entity Latest audited Balance Sheet date Shares of associate | joint arrangements held by the Company on the year end Description of significant influence Reason why the associate | joint arrangements are not consolidated Net worth attributable to shareholding as per the latest audited Balance Sheet Accumulated profit | (loss) Profit | (Loss) for the year No. Amount of investment Extent of holding % Considered in consolidation Not considered in consolidation Associate company 01. Valsad Institute of Medical Sciences Ltd March 31, 2025 13,50,000 22.50 50.00% NA 25.58 (3.80) (1.90) (1.90) Joint venture company 01. Rudolf Atul Chemicals Ltd March 31, 2025 29,18,750 6.13 50.00% Refer Note 1 NA 31.50 26.32 13.18 13.19 Joint operation 01. Anaven LLP March 31, 2025 67 50.00% Refer Note 2 NA 18.18 (48.84) 18.04 (18.04) Note 1: By representation on the Board of Directors of the joint venture company, the Company participation in the policy making process. Note 2: This is a jointly controlled entity. 306 306 Integrated Annual Report 2024-25
RkJQdWJsaXNoZXIy MjA2MDI2